 |
|
Nevirapine and Zidovudine at Birth to Reduce Perinatal Transmission of HIV in an African Setting
A Randomized Controlled Trial
Taha E. Taha, MBBS, PhD;
Newton I. Kumwenda, PhD;
Donald R. Hoover, PhD;
Susan A. Fiscus, PhD;
George Kafulafula, MBBS, FCOG;
Chiwawa Nkhoma, MSc;
Samah Nour, MBBCh;
Shu Chen, MSc;
George Liomba, MBBS, FRCPath;
Paolo G. Miotti, MD;
Robin L. Broadhead, MBBS, FRCP
JAMA. 2004;292:202-209.
Context Antenatal counseling and human immunodeficiency virus (HIV) testing are not universal in Africa; thus, women often present in labor with unknown HIV status without receiving the HIVNET 012 nevirapine (NVP) regimen (a single oral dose of NVP to the mother at the start of labor and to the infant within 72 hours of birth).
Objective To determine risk of mother-to-child transmission of HIV when either standard use of NVP alone or in combination with zidovudine (ZDV) was administered to infants of women tested at delivery.
Design, Setting, and Participants A randomized, open-label, phase 3 trial conducted between April 1, 2000, and March 15, 2003, at 6 clinics in Blantyre, Malawi, Africa. The trial included all infants born to 894 women who were HIV positive, received NVP intrapartum, and were previously antiretroviral treatment–naive. Infants were randomly assigned to NVP (n = 448) and NVP plus ZDV (n = 446). Infants were enrolled at birth, observed at 6 to 8 weeks, and followed up through 3 to 18 months. The HIV status of 90% of all infants was established at 6 to 8 weeks.
Intervention Mothers received a 200-mg single oral dose of NVP intrapartum and infants received either 2-mg/kg oral dose of NVP or NVP (same dose) plus 4 mg/kg of ZDV twice per day for a week.
Main Outcome Measures HIV infection of infant at birth and 6 to 8 weeks, and adverse events.
Results The mother-to-child transmission of HIV at birth was 8.1% (36/445) in infants administered NVP only and 10.1% (45/444) in those administered NVP plus ZDV (P = .30). A life table estimate of transmission at 6 to 8 weeks was 14.1% (95% confidence interval [CI], 10.7%-17.4%) in infants who received NVP and 16.3% (95% CI, 12.7%-19.8%) in those who received NVP plus ZDV (P = .36). For infants not infected at birth and retested at 6 to 8 weeks, transmission was 6.5% (23/353) in those who received NVP only and 6.9% (25/363) in those who received NVP plus ZDV (P = .88). Almost all infants (99%-100%) were breastfed at 1 week and 6 to 8 weeks. Grades 3 and 4 adverse events were comparable; 4.9% (22/448) and 5.4% (24/446) in infants receiving NVP only and NVP plus ZDV, respectively (P = .76).
Conclusions The frequency of mother-to-child HIV transmission at 6 to 8 weeks in our 2 study groups was comparable with that observed for other perinatal HIV intervention studies among breastfeeding women in Africa. The safety of the regimen containing neonatal ZDV was similar to that of a standard NVP regimen.
Author Affiliations: Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Md (Drs Taha, Kumwenda, and Nour, and Ms Chen); Department of Statistics and Institute for Health, Health Care Policy and Aging Research, Rutgers University, Piscataway, NJ (Dr Hoover); Department of Microbiology and Immunology, University of North Carolina, Chapel Hill (Dr Fiscus); College of Medicine, University of Malawi (Drs Kafulafula, Liomba, and Broadhead) and Johns Hopkins University-College of Medicine-Ministry of Health Research Project (Ms Nkhoma), Blantyre, Malawi; and Office of AIDS Research, National Institutes of Health, Bethesda, Md (Dr Miotti).
RELATED ARTICLE
Treatment of HIV/AIDS: Do the Dilemmas Only Increase?
Merle A. Sande and Allan Ronald
JAMA. 2004;292(2):266-268.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Extended Antiretroviral Prophylaxis to Reduce Breast-Milk HIV-1 Transmission
Kumwenda et al.
NEJM 2008;359:119-129.
ABSTRACT
| FULL TEXT
Suppression of Viremia and Evolution of Human Immunodeficiency Virus Type 1 Drug Resistance in a Macaque Model for Antiretroviral Therapy
Ambrose et al.
J. Virol. 2007;81:12145-12155.
ABSTRACT
| FULL TEXT
Sensitivity of the ViroSeq HIV-1 Genotyping System for Detection of the K103N Resistance Mutation in HIV-1 Subtypes A, C, and D
Church et al.
J. Mol. Diagn. 2006;8:430-432.
ABSTRACT
| FULL TEXT
Evidence behind the WHO Guidelines: Hospital Care for Children: What Antiretroviral Agents and Regimens are Effective in the Prevention of Mother-to-child Transmission of HIV?
Nightingale and Dabis
J Trop Pediatr 2006;52:235-238.
FULL TEXT
Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission
Palmer et al.
Proc. Natl. Acad. Sci. USA 2006;103:7094-7099.
ABSTRACT
| FULL TEXT
Affordable, Abbreviated Roche Monitor Assay for Quantification of Human Immunodeficiency Virus Type 1 RNA in Plasma
Fiscus et al.
J. Clin. Microbiol. 2005;43:4200-4202.
ABSTRACT
| FULL TEXT
Prenatal Screening for HIV: A Review of the Evidence for the U.S. Preventive Services Task Force
Chou et al.
ANN INTERN MED 2005;143:38-54.
ABSTRACT
| FULL TEXT
Gender Differences in Perinatal HIV Acquisition Among African Infants
Taha et al.
Pediatrics 2005;115:e167-e172.
ABSTRACT
| FULL TEXT
Reducing HIV Transmission from Mothers to Newborns
JWatch Women's Health 2004;2004:5-5.
FULL TEXT
Interrupting Mother-to-Infant Transmission of HIV
JWatch Infect. Diseases 2004;2004:1-1.
FULL TEXT
Treatment of HIV/AIDS: Do the Dilemmas Only Increase?
Sande and Ronald
JAMA 2004;292:266-268.
FULL TEXT
|
